New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting
MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro
2024 has started on a low for US biotech Anavex Life Sciences, which saw its shares fall sharply this morning after Rett syndrome candidate Anavex 2-73 failed a clinical t
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan
New data from NHS England has revealed that the waiting list for community health services has topped one million for the first time, with children and young people dispro
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor